Zentalis Pharmaceuticals (ZNTL) News Today $1.36 -0.09 (-6.21%) Closing price 05/5/2025 04:00 PM EasternExtended Trading$1.34 -0.02 (-1.40%) As of 05/5/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Almitas Capital LLC Raises Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)Almitas Capital LLC grew its holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 69.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,626,896 shares of the compaMay 4 at 7:45 AM | marketbeat.comBoxer Capital Management LLC Makes New $1.36 Million Investment in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)Boxer Capital Management LLC acquired a new stake in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 450,000 shares of the company's stock, valuedMay 4 at 6:25 AM | marketbeat.comZentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 1, 2025 | globenewswire.comZentalis Pharmaceuticals (ZNTL) to Release Earnings on TuesdayZentalis Pharmaceuticals (NASDAQ:ZNTL) will be releasing earnings before the market opens on Tuesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-6-zentalis-pharmaceuticals-inc-stock/)May 1, 2025 | marketbeat.comScott Dunseth Myers Purchases 21,000 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) StockMay 1, 2025 | insidertrades.comBrokerages Set Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) PT at $8.24May 1, 2025 | americanbankingnews.comZentalis shares insights on cancer research at AACRApril 29, 2025 | investing.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Recommendation of "Hold" by BrokeragesShares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) have been assigned a consensus rating of "Hold" from the nine research firms that are covering the company, Marketbeat.com reports. Five equities research analysts have rated the stock with a hold recommendation and four haveApril 29, 2025 | marketbeat.comZentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROCApril 28, 2025 | globenewswire.comDecheng Capital LLC Trims Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)Decheng Capital LLC reduced its position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 24.8% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 2,338,095 shares of the company's stock after selling 770,000 shares during the period. Zentalis PharmApril 28, 2025 | marketbeat.comWalleye Capital LLC Makes New $587,000 Investment in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)Walleye Capital LLC acquired a new stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 193,709 shares of the company's stock, valued at approximately $April 25, 2025 | marketbeat.comJPMorgan Chase & Co. Boosts Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)JPMorgan Chase & Co. lifted its holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 75.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 859,710 shares of the company's stock after acquiring an additional 370,511 shares dApril 25, 2025 | marketbeat.comZentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual MeetingApril 23, 2025 | globenewswire.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Rating of "Hold" by BrokeragesZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) has received an average rating of "Hold" from the nine brokerages that are covering the firm, MarketBeat.com reports. Five equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendaApril 4, 2025 | marketbeat.comZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 1, 2025 | globenewswire.comWhat is HC Wainwright's Forecast for ZNTL Q1 Earnings?Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Stock analysts at HC Wainwright dropped their Q1 2025 earnings per share (EPS) estimates for Zentalis Pharmaceuticals in a research report issued to clients and investors on Thursday, March 27th. HC Wainwright analyst A. Fein now forecaMarch 31, 2025 | marketbeat.comLeerink Partnrs Has Pessimistic Outlook of ZNTL Q1 EarningsZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Equities research analysts at Leerink Partnrs dropped their Q1 2025 earnings per share estimates for shares of Zentalis Pharmaceuticals in a research report issued on Wednesday, March 26th. Leerink Partnrs analyst A. Berens now anticipaMarch 31, 2025 | marketbeat.comWedbush Reaffirms Neutral Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL)Wedbush reissued a "neutral" rating and issued a $4.00 price target on shares of Zentalis Pharmaceuticals in a report on Friday.March 29, 2025 | marketbeat.comZentalis Pharmaceuticals (NASDAQ:ZNTL) Posts Earnings Results, Beats Expectations By $0.09 EPSZentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) posted its earnings results on Wednesday. The company reported ($0.66) EPS for the quarter, topping analysts' consensus estimates of ($0.75) by $0.09. The firm had revenue of $26.90 million for the quarter.March 28, 2025 | marketbeat.comHC Wainwright Reaffirms Buy Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL)HC Wainwright reiterated a "buy" rating and issued a $10.00 target price on shares of Zentalis Pharmaceuticals in a research note on Thursday.March 28, 2025 | marketbeat.comStifel Nicolaus Sticks to Their Buy Rating for Zentalis Pharmaceuticals (ZNTL)March 27, 2025 | markets.businessinsider.comZentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational UpdatesMarch 26, 2025 | globenewswire.comZentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025March 25, 2025 | globenewswire.comZentalis Pharmaceuticals' (ZNTL) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $10.00 target price on shares of Zentalis Pharmaceuticals in a research report on Monday.March 18, 2025 | marketbeat.comZentalis presents updated clinical data on azenosertib as SGO 2025March 16, 2025 | markets.businessinsider.comZentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s CancerMarch 15, 2025 | finance.yahoo.comZentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's CancerMarch 15, 2025 | globenewswire.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of "Hold" from BrokeragesShares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) have received a consensus rating of "Hold" from the nine analysts that are currently covering the stock, Marketbeat reports. Five analysts have rated the stock with a hold rating and four have given a buy rating to the companMarch 9, 2025 | marketbeat.comZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 3, 2025 | globenewswire.comZentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s CancerMarch 3, 2025 | markets.businessinsider.comZentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's CancerMarch 3, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTLFebruary 25, 2025 | prnewswire.comZentalis Pharmaceuticals to Participate in Upcoming Investor ConferencesFebruary 24, 2025 | globenewswire.comZentalis Pharmaceuticals (ZNTL): Among Cheapest Stocks Insiders Are Buying RecentlyFebruary 21, 2025 | msn.com10 Cheapest Stocks Insiders Are Buying RecentlyFebruary 20, 2025 | insidermonkey.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTLFebruary 18, 2025 | prnewswire.comZentalis Pharmaceuticals (ZNTL) Expected to Announce Quarterly Earnings on TuesdayZentalis Pharmaceuticals (NASDAQ:ZNTL) will be releasing earnings before the market opens on Tuesday, February 25.February 18, 2025 | marketbeat.comZentalis Pharmaceuticals' chief medical officer acquires $45,656 in stockFebruary 13, 2025 | msn.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Insider Ingmar Bruns Purchases 20,000 SharesFebruary 13, 2025 | insidertrades.comInsider Buying: Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Insider Buys 20,000 Shares of StockZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) insider Ingmar Bruns bought 20,000 shares of the stock in a transaction dated Thursday, February 6th. The stock was bought at an average cost of $2.28 per share, with a total value of $45,600.00. Following the purchase, the insider now owns 36,629 shares in the company, valued at $83,514.12. The trade was a 120.27 % increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.February 12, 2025 | marketbeat.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Rating of "Hold" by AnalystsZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) has received a consensus rating of "Hold" from the nine research firms that are presently covering the stock, MarketBeat.com reports. Five analysts have rated the stock with a hold rating and four have issued a buy rating on the compaFebruary 12, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTLFebruary 11, 2025 | prnewswire.comQ3 Earnings Forecast for ZNTL Issued By Leerink PartnrsZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Investment analysts at Leerink Partnrs issued their Q3 2025 earnings per share estimates for shares of Zentalis Pharmaceuticals in a research report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens expects that the cFebruary 10, 2025 | marketbeat.comQ1 Earnings Forecast for ZNTL Issued By Leerink PartnrsZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Zentalis Pharmaceuticals in a note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst A. Berens anticipates that the company will postFebruary 7, 2025 | marketbeat.comZentalis Pharmaceuticals chief legal officer sells $22,643 in stockFebruary 5, 2025 | msn.comZentalis pharmaceuticals officer sells $24,590 in stockFebruary 5, 2025 | msn.comInsider Buying: Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Director Buys 60,000 Shares of StockFebruary 5, 2025 | insidertrades.comZentalis pharmaceuticals director Jan Skvarka buys $103,446 in stockFebruary 4, 2025 | msn.comZentalis pharmaceuticals director Luke Walker buys $24,966 in stockFebruary 4, 2025 | msn.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Director Jan Skvarka Purchases 60,000 SharesZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) Director Jan Skvarka bought 60,000 shares of the stock in a transaction dated Friday, January 31st. The stock was bought at an average price of $1.72 per share, with a total value of $103,200.00. Following the acquisition, the director now owns 149,551 shares in the company, valued at approximately $257,227.72. This represents a 67.00 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.February 4, 2025 | marketbeat.com Get Zentalis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ZNTL and its competitors with MarketBeat's FREE daily newsletter. Email Address ZNTL Media Mentions By Week ZNTL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ZNTL News Sentiment▼0.670.72▲Average Medical News Sentiment ZNTL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ZNTL Articles This Week▼83▲ZNTL Articles Average Week Get Zentalis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ZNTL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ERAS News Today SANA News Today ZVRA News Today ALT News Today SNDL News Today ORKA News Today KMDA News Today RVNC News Today TECX News Today AUTL News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ZNTL) was last updated on 5/6/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s Bitcoin Reserve is No Accident…Crypto policy is changing fast… Smart investors are positioning themselves to benefit. And it's all happeni...Crypto 101 Media | SponsoredElon Musk is all in on these robots …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zentalis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zentalis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ZNTL Stock Free ZNTL Stock Alerts